Level of Evidence: 1b. < Levodopa < Levodopa therapy

Facettes :

List of bibliographic references indexed by Levodopa

Number of relevant bibliographic references: 18.

Ident.	Authors (with country if any)	Title
001A50 (2001)	T. Caraceni [Italie] ; M. Musicco [Italie]	Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study
001C37 (2000)	A. P Strafella [Italie] ; F. Valzania [Italie] ; S. A Nassetti [Italie] ; A. Tropeani [Italie] ; A. Bisulli [Italie] ; M. Santangelo [Italie] ; C. A Tassinari [Italie]	Effects of chronic levodopa and pergolide treatment on cortical excitability in patients with Parkinson's disease: a transcranial magnetic stimulation study
001D26 (1999)	William J. Weiner [États-Unis]	The initial treatment of Parkinson's disease should begin with levodopa
001E63 (1998)	Rascol [France] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Amos D. Korczyn [Israël] ; Warner H. Poewe [Autriche] ; Fabrizzio Stocchi [Italie]	Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study
001E89 (1998)	Patriciac. Poluha [États-Unis] ; Hans-Leo Teulings [États-Unis] ; Roberth. Brookshire [États-Unis]	Handwriting and speech changes across the levodopa cycle in Parkinson’s disease
001E96 (1998)	John D. O'Sullivan [Australie] ; Catherine M. Said [Australie] ; Louise C. Dillon [Australie] ; Marion Hoffman [Australie] ; Hughes [Australie]	Gait analysis in patients with Parkinson's disease and motor fluctuations: Influence of levodopa and comparison with other measures of motor function
001F84 (1997)	Larsen [Norvège] ; Jette Boas [Danemark]	The effects of early selegiline therapy on long‐term levodopa treatment and parkinsonian disability: An interim analysis of a norwegian–danish 5‐year study
001F94 (1997)	P. Stanzione [Italie] ; R. Traversa [Italie] ; M. Pierantozzi [Italie] ; R. Semprini [Italie] ; M. Loberti [Italie] ; A. Peppe [Italie] ; A. M. Santilli [Italie] ; G. Bernardi [Italie]	SEPs N30 amplitude in Parkinson's disease and in pharmacologically induced rigidity: relationship with the clinical status
002129 (1996)	J. Boas [Danemark] ; J. Worm-Petersen [Danemark] ; E. Dupont [Danemark] ; B. Mikkelsen [Danemark] ; L. Wermuth [Danemark]	The levodopa dose‐sparing capacity of pergolide compared with that of bromocriptine in an open‐label, crossover study
002198 (1996)	Roos [Pays-Bas] ; J. C. F. Jongen [Pays-Bas] ; E. A. Van Der Velde [Pays-Bas]	Clinical course of patients with idiopathic Parkinson's disease
002335 (1995)	Clarke [Royaume-Uni]	Does levodopa therapy delay death in Parkinson's disease? A review of the evidence
002359 (1995)	Przedborski [États-Unis] ; Vernice Jackson-Lewis [États-Unis] ; Stanley Fahn [États-Unis]	Antiparkinsonian therapies and brain mitochondrial complex I activity
002428 (1994)	Roberto Marconi [France, Italie] ; Dominique Lefebvre-Caparros [France] ; Anne-Marie Bonnet [France] ; Marie Vidailhet [France] ; Bruno Dubois [France] ; Agid [France]	Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology
002462 (1994)	Olanow [États-Unis] ; S. Fahn [États-Unis] ; M. Muenter [États-Unis] ; H. Klawans [États-Unis] ; H. Hurtig [États-Unis] ; M. Stern [États-Unis] ; I. Shoulson [États-Unis] ; R. Kurlan [États-Unis] ; J. D. Grimes [Canada] ; Joseph Jankovic [États-Unis] ; M. Hoehn [États-Unis] ; C. H. Markham [États-Unis] ; R. Duvisin [États-Unis] ; O. Reinmuth [États-Unis] ; H. A. Leonard [États-Unis] ; E. Ahlskog [États-Unis] ; R. Feldman [États-Unis] ; L. Hershey [États-Unis] ; M. D. Yahr [États-Unis]	A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease
002550 (1993)	Factor [États-Unis] ; William J. Weiner [États-Unis]	Early combination therapy with bromocriptine and levodopa in parkinson's disease
002625 (1992)	María Angeles Mena ; Beatriz Pardo ; María José Casarejos ; Stanley Fahn [États-Unis] ; Justo García De Yébenes [Espagne]	Neurotoxicity of levodopa on catecholamine‐rich neurons
002691 (1991)	Fabio Baronti [États-Unis] ; Katherine E. Conant [États-Unis] ; Marianne Giuffra [États-Unis] ; Thomas L. Davis [États-Unis] ; Giorgio Brughitta [États-Unis] ; Michael J. Iadarola [États-Unis] ; Wade H. Berrettini [États-Unis] ; Thomas N. Chase [États-Unis] ; M. Maral Mouradian [États-Unis]	Opioid peptides in Parkinson's disease: effects of dopamine repletion
002A04 (1985)	S. Kaakkola [Finlande] ; P. T. M Nnistö [Finlande] ; E. Nissinen [Finlande] ; A. Vuorela [Finlande] ; R. M Ntyl [Finlande]	The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Levodopa" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Levodopa" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Levodopa
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024